Tau Protein
Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.
All Product Categories
-
Tau Protein Related Products (217)
Related Products (217)
-
Antibodies (5)
-
BChE/HDAC6-IN-2
0 ImagesCat. No.: HY-149418CAS No.: 2925457-33-4BChE/HDAC6-IN-2 (compound 29a) is a dual inhibitor of BChE and HDAC6 with IC50s of 1.8 nM and 71.0 nM, respectively. BChE/HDAC6-IN-2 has prominently neuroprotective effects and reactive oxygen species (ROS) scavenging activity. BChE/HDAC6-IN-2 is also an effective chelator of metal ion (Fe2+ and Cu2+). BChE/HDAC6-IN-2 inhibits phosphorylation of tau, and exhibits moderate immunomodulatory effect.
-
TBL-100
0 ImagesCat. No.: HY-P991377TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research.
-
MAO-B-IN-45
0 ImagesCat. No.: HY-176271CAS No.: 3069915-36-9MAO-B-IN-45 is a dual inhibitor of ferroptosis and MAO-B. MAO-B-IN-45 shows selectivity towards MAO-B with an IC50 of 87.47 nM and selectivity exceeding 229-fold for MAO-B over MAO-A. MAO-B-IN-45 has excellent antiferroptosis activity through modulation of the iron metabolic pathway and GSH-GPX4 axis in vitro. MAO-B-IN-45 improves cognitive and behavioral impairments in 3×Tg (APP/Tau/Ps1) AD mouse and significantly reduced the levels of ferritin heavy chain 1 (FTH1), APP, and Tau phosphorylation (p-Tau) proteins in the brain.
-
Tau Peptide (379-408)
0 ImagesCat. No.: HY-P4969CAS No.: 1246357-53-8Tau Peptide (379-408) is aTau fragment.
-
Multitarget AD-IN-8
0 ImagesCat. No.: HY-189262Multitarget AD-IN-8 is a blood-brain barrier-penetrant, orally active multitarget inhibitor. Multitarget AD-IN-8 inhibits abnormal Tau phosphorylation at Thr181 and Ser396 sites and attenuates NF-κB phosphorylation. Multitarget AD-IN-8 downregulates BACE1 expression to reduce Aβ production, inhibits the Bax/Bcl-2 pathway, and suppresses Caspase-1 activation. Multitarget AD-IN-8 attenuates p38, ERK1/2, and JNK phosphorylation and inhibits Aβ25-35-induced Apoptosis. Multitarget AD-IN-8 exhibits neuroprotective effects against Aβ25-35-induced injury, ameliorates learning and memory deficits in AD mouse models, and alleviates hippocampal neuronal pathological damage. Multitarget AD-IN-8 can be used for research on Alzheimer's disease.
-
Acetyl-PHF5 amide
0 ImagesCat. No.: HY-P4822CAS No.: 1190970-24-1Acetyl-PHF5 amide is an amyloidogenic protein tau peptide. Acetyl-PHF5 amide can polymerization into filamentous structures.
-
TNIR7-1A
0 ImagesCat. No.: HY-155383CAS No.: 2301931-35-9TNIR7-1A is a fused cycloheptatriene–BODIPY derivative that displays properties favorable for near-infrared (NIR) imaging (Ex/Em = 600/774 nm in PBS) with high affinity and specificity to Neurofibrillary tangles (NFTs) in vitro. TNIR7-1A effectively penetrated the blood–brain barrier.
-
Anti-Mouse/Human PrP/prion protein Antibody (TW1)
0 ImagesCat. No.: HY-P990167Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD).
-
GSK-3β/G9a-IN-1
0 ImagesCat. No.: HY-W657887CAS No.: 154866-92-9GSK-3β/G9a-IN-1 (Compound T2) is an orally active, selective, blood-brain-barrier permeable, competitive G9a (substrate-competitive, IC50: 1.1 μM) and GSK-3β (ATP competitive, IC50: 0.8 μM) inhibitor. GSK-3β/G9a-IN-1 is a potent H3K9me2 inhibitor that reshapes chromatin landscape. GSK-3β/G9a-IN-1 lowers tau phosphorylation, reduces Aβ aggregation. GSK-3β/G9a-IN-1 displays inhibition toward glucocorticoid receptor, androgen receptor, and alpha-2A adrenergic receptor. GSK-3β/G9a-IN-1 also upregulates SAGA complex members such as Eny2 and Sgf29. GSK-3β/G9a-IN-1 markedly improves memory, restores social behaviors, and increases synaptic complexity in late-onset Alzheimer’s disease.
-
SCR1693
0 ImagesCat. No.: HY-165341CAS No.: 1442559-20-7SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
-
FO-4-15
0 ImagesFO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
-
GSK-3β/HDAC-IN-2
0 ImagesCat. No.: HY-174398GSK-3β/HDAC-IN-2 is a potent inhibitor of GSK-3β (IC50 = 0.04 μM), HDAC2 (IC50 = 1.05 μM, Ki = 0.070 μM) and HDAC6 (IC50 = 1.52 μM, Ki = 0.017 μM). GSK-3β/HDAC-IN-2 inhibits HDAC2 and HDAC6 activities and blocks tau hyperphosphorylation. GSK-3β/HDAC-IN-2 exerts neuroprotective effects and shows no significant toxicity. GSK-3β/HDAC-IN-2 can be used in the research of Alzheimer's disease.
-
PROTAC GSK3 degrader-1
0 ImagesCat. No.: HY-185634PROTAC GSK3 degrader-1 is a potent, blood-brain barrier-permeable GSK3 PROTAC degrader, with a DC50 of 1.4 nM against GSK3β. PROTAC GSK3 degrader-1 exerts equally potent degradation activity against both GSK3α and GSK3β. It inhibits the phosphorylation of CRMP2, PRKAA1 and Tau, and stabilizes β-catenin. PROTAC GSK3 degrader-1 can be used in the research of Alzheimer's disease and Parkinson's disease.
-
GSK-3β inhibitor 24
0 ImagesCat. No.: HY-168857CAS No.: 3069913-37-4GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects.
-
8-F-2-(Me-Pip-Me)-Tryptanthrin
0 ImagesCat. No.: HY-184078CAS No.: 1563106-65-98-F-2-(Me-Pip-Me)-Tryptanthrin is a tryptanthrin derivative with blood-brain barrier penetration. 8-F-2-(Me-Pip-Me)-Tryptanthrin protects neurons from Aβ-induced apoptosis, inhibits Aβ-induced Tau protein hyperphosphorylation and neuronal synaptic damage, and improves learning and memory abilities in Alzheimer's disease mice. 8-F-2-(Me-Pip-Me)-Tryptanthrin can be used for the research of nervous system diseases, including diseases related to abnormal Tau protein phosphorylation and abnormal PSD-95 function.
-
Drofenine
0 ImagesDrofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC50 of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with Ki of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm.
-
Keap1-Nrf2-IN-30
0 ImagesCat. No.: HY-184761Keap1-Nrf2-IN-30 is an orally active, blood-brain barrier-permeable Keap1-Nrf2 protein-protein interaction inhibitor with a Keap1 Kd value of 157 nM. Keap1-Nrf2-IN-30 selectively inhibits the Keap1-Nrf2 protein-protein interaction, promotes Nrf2 nuclear translocation, suppresses induced ferroptosis, reduces the expression of Aβ and p-Tau, and upregulates the expression of GPX4 and SLC7A11. Keap1-Nrf2-IN-30 upregulates the expression of HO-1 and NQO1, alleviates neuronal damage, and improves cognitive and spatial memory deficits. Keap1-Nrf2-IN-30 can be used in the research of Alzheimer's disease.
-
DA5-CH
0 ImagesCat. No.: HY-P12141CAS No.: 2227651-65-0Synonyms: KP405DA5-CH (KP405) is a blood-brain barrier-permeable GLP-1/GIP receptor agonist. DA5-CH activates GLP-1 and GIP receptors, inhibits the NF-κB inflammatory pathway, reduces α-synuclein (α-synuclein) levels, restores the expression of tyrosine hydroxylase and neurotrophic factors, improves motor function, decreases amyloid plaques and phosphorylated tau protein levels in the hippocampus, restores synaptic plasticity, regulates the PI3K/AKT/GSK3β and CREB signaling pathways, and alleviates mitochondrial stress. DA5-CH can be used for research on Parkinson's disease and Alzheimer's disease.
